Printer Friendly

Innovent announces CFDA IND approval for Anti-CD47 Antibody IBI188.

M2 EQUITYBITES-September 10, 2018-Innovent announces CFDA IND approval for Anti-CD47 Antibody IBI188


Biopharmaceutical company Innovent Biologics disclosed on Friday that its IND application for IBI188 has been approved by the National Medical Products Administration (NMPA, or CFDA) for clinical trials to assess its safety and efficacy for multiple tumour types, including non-Hodgkin's lymphoma and ovarian cancer.

According to the Chinese company, IBI188 is a fully human anti-CD47 monoclonal antibody (mAb) drug candidate and its fourth IND approval this year. CD47 is one of the most important targets in immuno-oncology and will be among one of a few companies pursuing the development of an anti-CD47 antibody in the early clinical stage.

In conjunction, CD47 is regarded by many experts to have the possibility of becoming the next "star" in the field of immuno-oncology following the ground-breaking success of PD1 / PD-L1 antibodies. the company has advanced IBI188 as a leading player for this target to enter into clinical development stage.

Both in vitro and in vivo experiments showed that IBI188 can bind to the CD47 antigen on the surface of tumour cells, block the CD47-SIRP? signalling pathway, inhibit the "Don't Eat Me" signal and promote the phagocytosis of tumour cells by macrophages, exerting an anti-tumour effect. It has stronger receptor blocking ability than similar drugs, concluded the company.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 10, 2018
Previous Article:Panostaja reports on transfer of shares as board fees.
Next Article:Carwale reveals details of updated version of Ford Aspire.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters